Given proinsulin folding relies on this coordinated UPR activity, including the ATF6 and IRE1α-XBP1 pathways, targeting the UPR, and specifically these pathways, offers a novel therapeutic avenue for diabetes. This evidence concerns the gene INS and diabetes mellitus.